CG From the
-
2024: The Year of Development in Cell Therapy
4/10/2024
We break down three trends driving development in cell therapy in 2024.
-
Nanoscope Therapeutics Tackling Vision Loss With Ocular Gene Therapy
3/27/2024
Leaders from Nanoscope Therapeutics explain the safety and efficacy data from as well as next steps for the company's RESTORE trial.
-
ICYMI: Q1 2024’s Cell & Gene Live And Cell & Gene: The Podcast
3/27/2024
With Q1 of 2024 coming to close, I wanted to take this opportunity to make sure you’ve read, heard, or viewed some of insightful content we’ve created for Cell & Gene's readers since the start of the year.
-
Inside Tenaya Therapeutics’ AAV9-Based Gene Therapy
3/27/2024
Tenaya Therapeutics' CSO explains how the company's gene therapy, TN-401, may treat heart disease.
-
Improving AAV Purity Upstream With PCL Manufacturing
3/21/2024
The downstream separation of AAV capsids affects end-product purity and has been identified as a key pain point of the industry. Ultragenyx’s Dennis Huang advises starting with higher-quality yields upstream.
-
Do ClinOps Professionals Understand The CAR-T Supply Chain?
3/4/2024
Lee Clough RN, HP, of Novartis talks about the importance of understanding the nuances associated with collecting and shipping autologous material (i.e., CAR-Ts) for clinical trials.
-
Rare Disease Day 2024
2/29/2024
Today is Rare Disease Day 2024, a global initiative to raise awareness and generate support for everyone who is on a rare medical journey.
-
Video Clips From Cell & Gene Live: 2024 Regulatory Outlook With FDA's Dr. Peter Marks And Dr. Nicole Verdun
2/27/2024
Our recent Cell & Gene Live, 2024 Regulatory Outlook With FDA's Drs. Peter Marks and Nicole Verdun, was a chock full of data and valuable information. I've broken down the full-length presentation into bite sized video clips that you can view at your convenience.
-
Inside Cell & Gene Live “How To Reduce Batch-To-Batch Variation In Cell Therapy Manufacturing”
2/26/2024
Here's a recap of our recent Cell & Gene Live, How to Reduce Batch-to-Batch Variation in Cell Therapy Manufacturing, featuring expert panelists, Omkar Kawalekar, Ph.D., Head of Manufacturing and Supply Chain at NextGen Therapies Consulting at Deloitte and Donna Rill, Chief Technology Officer at Triumvira Immunologics.
-
Mass General Cancer Center’s Dr. Genevieve Boland on Amtagvi Approval
2/26/2024
The FDA’s approval of Amtagvi addresses an unmet need in melanoma patient care. Here, Genevieve Boland, M.D., Ph.D., from Mass General Cancer Center shares her insight on the approval.